Fibroblast proliferation and fibrosis pathways

Fibroblast proliferation and fibrosis pathways represent a coordinated series of cellular and molecular events that lead to the accumulation of excess fibrous connective tissue in an organ or tissue (Wynn, 2008). This process is typically initiated by tissue injury, which triggers the activation of fibroblasts into myofibroblasts, characterized by the expression of alpha-smooth muscle actin (α-SMA) and increased production of extracellular matrix (ECM) proteins like collagen (Meng et al., 2016). Key signaling molecules such as Transforming Growth Factor-beta (TGF-β), Platelet-Derived Growth Factor (PDGF), and Fibroblast Growth Factor (FGF) play pivotal roles in driving these pathways. Pathological fibrosis is a hallmark of many chronic diseases, including idiopathic pulmonary fibrosis and cirrhosis, where the overproduction of ECM disrupts normal organ architecture and function. Current pharmacological interventions, such as nintedanib and pirfenidone, aim to modulate these pathways by inhibiting specific growth factor receptors or downstream signaling components to slow disease progression (Richeldi et al., 2014; King et al., 2014).

Other names

FibrogenesisMyofibroblast activationTissue remodelingExtracellular matrix (ECM) depositionFibrotic signaling

Inhibition of tyrosine kinase receptors (VEGFR, PDGFR, FGFR) and modulation of TGF-beta signaling to reduce fibroblast activation, proliferation, and extracellular matrix deposition (Richeldi et al., 2014; Meng et al., 2016).